Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a clinical-stage biopharmaceutical company is currently down (-3.47%) after reporting a smaller fourth-quarter loss Monday, but said it is still waiting for federal regulators to make a decision about the status of its weight loss drug Belviq. Arena said it lost $21.3 million in the fourth quarter, compared to $23.7 million in the fourth quarter of 2011. Arena sold more than 70 million new shares of stock in 2012, so its per-share loss decreased to 10 cents from 16 cents. Revenue fell to $1.9 million from $2.1 million which as prompted Growing Stock Report to add Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to their Nasdaq Biotech Watch List.
To see what other Investors are saying about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)Click Here: http://www.growingstockreport.com/Survey.aspx?stock=ARNA&SubId=AW
VIVUS Inc. (NASDAQ:VVUS) a biopharmaceutical company, is developing therapies to address obesity, sleep apnea, diabetes, and male sexual health recently reported fourth-quarter revenue that was half of what analysts expected due to sluggish sales of its weight loss drug, Qsymia. VIVUS Inc. (NASDAQ:VVUS)is currently down (-67.7%) from it's 52 week High of $31.21 which has prompted Growing Stock Report to add the stock to their Nasdaq Biotech Watch List for this week.
To see what what other Investors are saying about VIVUS Inc. (NASDAQ:VVUS)
Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VVUS&SubId=AW
GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.Simply sign up for free and start receiving exclusive alerts.Subscribe Here: http://www.GrowingStockReport.com
Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Contact Info:Growing Stock Reporteditor@GrowingStockReport.com